These kinds of age distributions indicate that our center goodies a populace of patients who are cisplatin-ineligible due to co-morbidities rather than those who are ineligible solely due to age-related renal dysfunction. == Table 1 . or Kruskal-Wallis test. Clinical factors associated with VTEs were analyzed using conditional logistic regression stratified by treatment regimen. == Results == Among 198 patients, VTEs occurred in 13/51 (26%) GCbBev patients, 22/92 (24%) GCb patients and 8/55 (15%) GCis patients. Patient characteristics were significantly different between treatment cohorts in terms of age group, prior cystectomy, tumor near pelvic vessels, Khorana risk group Wogonoside and anti-platelet therapy. The type of chemotherapy Wogonoside was not associated with any VTEs or type of VTEs (arterial vs . venous). Prior cystectomy was associated with increased risk of VTEs (OR 2 . 2, 95% CI 1 . 04. 9, p=0. 047). == Conclusions == This is the largest series reporting VTEs in UC patients treated with firstline combination platinum-based therapy. The incidence of VTE in cisplatin-treated patients is similar to prior reports. However , the VTE price in carboplatin-treated patients had not been previously defined and thus represents a new baseline. The addition of bevacizumab does not appear to increase VTE risk. This high incidence of carboplatin-related VTEs justifies further study. Keywords: bladder cancer, thrombotic events, thromboembolic, urothelial carcinoma, deep venous thrombosis, pulmonary embolism, bevacizumab, carboplatin chemotherapy, cisplatin chemotherapy == INTRO == Cancer and cancer therapy, including chemotherapy and vascular endothelial growth element (VEGF) targeted therapies, have been associated with an increased incidence of VTEs: deep venous thrombosis (DVT), pulmonary embolus (PE), arterial thrombosis and embolus, cerebrovascular incident (CVA), and unstable angina (UA)/myocardial infarction (MI). A population-based case control study showed that VTE risk was increased sevenfold in patients with cancer. 1Patients with metastatic disease and the ones undergoing chemotherapy are at greatest risk of VTEs15and these events can be a leading cause of death in cancer patients. 4, 6, 7The hypercoagulable and thrombotic state in cancer patients may be due to multiple mechanisms including activation from the coagulation cascade through the release of cells factors Wogonoside and other procoagulants, changes in cellular blood components, increased platelet assimilation, and endothelial cell damage by tumor cells. 8Chemotherapeutics may magnify this effect and promote VTEs by worsening endothelial damage, enhancing platelet assimilation, and increasing oxidative damage leading to vascular toxicity. 9 The cancers thought to possess highest risk of chemotherapy-related VTEs are gastric and pancreas adenocarcinomas, with thoracic, lymphoma, gynecologic, bladder, and testicular cancers considered to have a moderate risk. 10Among platinum-based chemotherapy providers, cisplatin is reported to have a high incidence of treatment-related VTE. 9, 1114In a retrospective study of 932 patients with various tumor types treated Emr4 with cisplatin-based chemotherapy, there was an 18% incidence of VTEs. 15A separate meta-analysis exposed a significantly increased risk of VTEs associated with cisplatin-based regimens (RR, 1 . 67; 95% CI, 1 . 25 to 2 . 23; p=0. 01). 16Cisplatin-based chemotherapy combinations are standard, first-line treatment in advanced UC and are associated with a 13% incidence of venous thromboembolism. 17 While cisplatin is the treatment of choice in the neoadjuvant18, 19, adjuvant20, and advanced UC disease settings21, patients Wogonoside are often ineligible for the drug due to co-morbid factors such as age group, renal insufficiency, cardiac complications, and hearing loss. 22Carboplatin, an additional platinum-based agent, is frequently substituted for cisplatin based on a more favorable side effect profile. Although there is a clinical impression that VTEs occur at a lower rate in patients receiving platinum analogs such as carboplatin and oxaliplatin, there are minimal published data on these agents and their associated risk of VTEs. 9, 13, 23Gemcitabine is also frequently used in UC in combination with cisplatin or carboplatin. 21, 2428Gemcitabine in combination with a platinum-agent continues to be associated with increased thrombotic and vascular side effects14, 2931in contrast to studies on its use as a single agent in the treatment of UC. 27, 32, 33 In the treatment of advanced cancers, vascular endothelial growth factor (VEGF) inhibitors have been added to standard chemotherapy providers to improve overall survival, albeit at the expense of an obvious increased incidence of VTEs. A large meta-analysis Wogonoside (n=7, 956) demonstrated higher rates of all-grade (11. 9%) and high grade (6. 3%) venous thromboembolic.